Enliven Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-71.58	-37.66	-51.38	-49.22	-23.46	-11.34
Depreciation & Amortization	0.6	0.22	0.1	0.1	0.03	0
Share-Based Compensation	12.91	3.19	3.85	2.23	0.9	0.56
Other Operating Activities	-3.2	2.18	0.67	1.63	0.65	2.01
Operating Cash Flow	-61.27	-32.08	-46.77	-37.4	-21.88	-8.78
Capital Expenditures	-0.15	-0.61	-0.01	-0.02	-0.14	0
Change in Investments	-148.26	0	-1.62	-16.7	-23.92	0
Investing Cash Flow	-148.41	-0.61	-1.63	-16.72	-24.06	0
Share Issuance / Repurchase	161.76	0.59	49.68	81.45	0	0
Other Financing Activities	72.52	-2.39	-0.58	15.43	43.58	6.49
Financing Cash Flow	234.29	-1.8	49.1	96.88	43.58	6.49
Net Cash Flow	24.61	-34.49	0.7	42.76	-2.36	-2.29
Free Cash Flow	-61.42	-32.69	-46.78	-37.42	-22.02	-8.78
Free Cash Flow Per Share	-1.73	-10.46	-8.64	-10.75	-125.37	-49.98

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).